Use of medroxyprogesterone acetate (MAP) in lactating Holstein cows within an Ovsynch protocol: follicular growth and hormonal patterns.
To evaluate the effects of incorporating medroxyprogesterone acetate (MAP) in an Ovsynch protocol, cyclic lactating dairy cows were assigned randomly to two groups (control and MAP, n=8 each). Ovsynch treatment (Day 0: GnRH, Day 7: PG, Day 9: GnRH) was initiated at random stages of the estrous cycle (control) and an intravaginal polyurethane sponge impregnated with 300mg of MAP was inserted intravaginally in the MAP group at Day 0 and removed at Day 7 of the Ovsynch protocol (MAP treatment). Ovaries were scanned daily from Day 0 until the second GnRH treatment on Day 9 and from then every 6h for 36 h. Milk samples were collected three times weekly starting 17 days before the initiation of treatment to determine the stage of the cycle at the beginning of the Ovsynch protocol. Blood samples were collected to monitor estradiol (E2), progesterone (P4), LH, and 15-ketodihydro-PGF(2alpha) (PGFM) by RIA. Response to the first GnRH treatment varied with the stage of the cycle at the time of initiation of treatment, as cows in metestrous and late diestrous did not ovulate. In cows ovulating, growth rate of the new follicle was not affected by the addition of MAP. No treatment differences were found in E2 concentrations which reached a maximum at Day 9, consistent with the maximum follicular size. At Day 7, cows with luteal concentrations of P4 had increased concentrations of PGFM, but cows with basal P4 did not show an active release of prostaglandins. There were no treatment differences in the ovulatory response to the second GnRH-induced ovulation, with 11 of the 16 cows ovulating between 16 and 32 h. The addition of MAP to the Ovsynch protocol could not mimic the normal high progesterone levels needed to prevent premature ovulations in those cows with premature CL regression.
Cavestany
D
D
Instituto Nacional de Investigación Agropecuaria La Estanzuela, CC 39173, 70000 Colonia, Uruguay. cavestan@inia.org.uy
Meikle
A
A
Kindahl
H
H
Van Lier
E
E
Moreira
F
F
Thatcher
W W
WW
Forsberg
M
M
D000282:Administration, Intravaginal; D000818:Animals; D002417:Cattle / Q000502:physiology*; D015237:Dinoprost / Q000031:analogs & derivatives* / Q000097:blood; D004958:Estradiol / Q000097:blood; D030762:Estrous Cycle; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D006728:Hormones / Q000097:blood*; D007700:Kinetics; D007774:Lactation; D007986:Luteinizing Hormone / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D006080:Ovarian Follicle / Q000502:physiology*; D010062:Ovulation Induction / Q000662:veterinary; D011374:Progesterone / Q000097:blood; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*
D006728:Hormones; D011461:Prostaglandins F, Synthetic; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone; D015237:Dinoprost; D017258:Medroxyprogesterone Acetate; C049643:luprostenol